Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.
|Articles|April 24, 2020
COVID-19: What Lies Ahead in Mental Health?
Author(s)Michelle Riba, MD, MS, DFAPA, FAPM
Michelle Riba, MD, shares her thoughts on the days ahead.
Advertisement
Patients with depression, anxiety, and other mental health problems are going to need us more ever in the days ahead. Dr Riba is Professor and Associate Chair, University of Michigan Department of Psychiatry; Associate Director, University of Michigan Comprehensive Depression Center; and Deputy Editor in Chief Emeritus, Psychiatric Times. University of Michigan Department of Psychiatry has an excellent resources page on its website:
Advertisement
Related to this article
Ketamine or esketamine during C-section anesthesia lowers early postpartum depression symptom scores in trials, hinting at a new prevention approach under study.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
2
Burnout, Gratitude, and the Value of Staying Current: On the Mind of Gus Alva, MD, DFAPA
3
GLP-1 Receptor Agonists May Reinforce Restriction in Patients With Eating Disorders
4
Psychedelic Trials Reveal Gaps Between Controlled Efficacy and Real-World Readiness
5